Literature DB >> 3450844

Experimental impact of assay-dependent differences in plasma indocyanine green concentration determinations.

D M Grasela1, M L Rocci, P H Vlasses.   

Abstract

The purposes of the present investigation were (i) to directly compare in man, indocyanine green (ICG) plasma concentrations analyzed by high performance liquid chromatography (HPLC) vs. spectrophotometry; (ii) to evaluate whether the pharmacokinetic parameters generated for ICG from a clinical study are assay-dependent; (iii) to examine whether the method of pharmacokinetic analysis affects the magnitude of any assay-related differences observed in ICG's pharmacokinetic parameters; and (iv) to evaluate whether assay methodology and/or method of pharmacokinetic analysis affect the conclusions derived from a clinical study employing ICG as a marker for hepatic blood flow (HBF). Plasma samples obtained from a clinical study designed to assess the effects of cimetidine and posture on HBF were analyzed by spectrophotometry and HPLC. The spectrophotometric method overestimated ICG plasma concentrations when compared to HPLC. This finding is consistent with the observations of others suggesting the presence of a chemical impurity in the commercial ICG preparation. Data generated by the spectrophotometric method produced lower ICG clearance and HBF estimates and a longer ICG half-life regardless of the method of pharmacokinetic analysis. The method of pharmacokinetic data analysis had no effect on any pharmacokinetic parameter. The experimental conclusions derived from the clinical study were not affected by either analytical methodology or method of data analysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3450844     DOI: 10.1007/BF01068415

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  19 in total

1.  The handling of indocyanine green by the liver.

Authors:  G Paumgartner
Journal:  Schweiz Med Wochenschr       Date:  1975

2.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

3.  Determination of hepatic blood flow in man by cardio green.

Authors:  K WINKLER; N TYGSTRUP
Journal:  Scand J Clin Lab Invest       Date:  1960       Impact factor: 1.713

4.  Applications of dilution curves recorded from the right side of the heart or venous circulation with the aid of a new indicator dye.

Authors:  I J FOX; E H WOOD
Journal:  Proc Staff Meet Mayo Clin       Date:  1957-09-18

5.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

6.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

7.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

8.  High-pressure liquid chromatographic analysis of indocyanine green.

Authors:  P L Rappaport; J J Thiessen
Journal:  J Pharm Sci       Date:  1982-02       Impact factor: 3.534

9.  Physiological and pharmacological variability in estimated hepatic blood flow in man.

Authors:  T K Daneshmend; L Jackson; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

10.  Indocyanine green: pharmacokinetics in the rabbit and relevant studies of its stability and purity.

Authors:  R Heintz; C K Svensson; K Stoeckel; G J Powers; D Lalka
Journal:  J Pharm Sci       Date:  1986-04       Impact factor: 3.534

View more
  5 in total

1.  A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs.

Authors:  T C Krejcie; M J Avram; W B Gentry; C U Niemann; M P Janowski; T K Henthorn
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

2.  Use of parallel Erlang density functions to analyze first-pass pulmonary uptake of multiple indicators in dogs.

Authors:  T C Krejcie; J A Jacquez; M J Avram; C U Niemann; C A Shanks; T K Henthorn
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

3.  Clinical aspects of indocyanine green pharmacokinetics following portal vein administration.

Authors:  S Nishi; M Shindo; J Abe; A Asada
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

4.  Extent and variability of the first-pass elimination of adinazolam mesylate in healthy male volunteers.

Authors:  J C Fleishaker; H Friedman; S R Pollock
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

5.  Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.

Authors:  P A Soons; A De Boer; A F Cohen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.